Vol. 8 (05) pp. 505-511 DOI: 10.21474/IJAR01/10955

QUOI DE NEUF A PROPOS DE LHEPATITE VIRAL D:MISE AU POINT

, , , , , , , and
  • Faculte de Medecine et de Pharmacie, Universite Sidi Mohamed Ben Abdallah de Fes.
16 Downloads 64 Views
Crossref

Download Full Paper (PDF)

Article Analytics

References

  1. Brahmania M, Feld J, Arif A, et al. New therapeutic agents for chronic hepatitis?,B. Lancet Infect Dis 2016;16:e10‑
  2. Romeo R, Del Ninno E, Rumi M, et al. A 28-Year study of the course of hepatitis B infection : A risk factor for cirrhosis and hepatocellularcarcinoma. Gastroenterology 2009;136:1629‑
  3. Pir Ahmad Shah, Saad Choudhryet al , An update on the management of chronic hepatitis D, Gastroenterology Report, 7(6), 2019, 396?402?.
  4. Rizzetto M, Ciancio A. Epidemiologyof hepatitis D. Semin Liver Dis 2012;32: 211‑
  5. RizzettoM,CaneseMG,Aric?S,CrivelliO,TrepoC,BoninoF,etal.Immunofluorescencedetectionofnewantigen?antibody system (delta/anti-delta)associatedtohepatitisB virus inliverandinserumofHBsAgcarriers. Gut 1977;18(12):997?1003.
  6. RizzettoM,ShihJW,GockeDJ,PurcellRH,VermeG,GerinJL.Incidenceandsignificance of antibodiestodeltaantigeninhepatitisB virus infection. Lancet1979 ;2(8150):986?90.
  7. RizzettoM,PurcellRH,GerinJL.Epidemiol- ogyofHBVassociateddeltaagent: geogra- phicaldistributionofanti-deltaandprevalenceinpolytransfusedHBsAgcarriers. Lancet 1980;1(8180):1215?8.
  8. RizzettoM,HoyerB,CaneseMG,ShihJW, PurcellRH ,GerinJL. Deltaagent: association of deltaantigenwithhepatitisBsurfaceanti- gen and RNAinserumofdelta-infectedchim- panzees.ProcNatlAcadSciUSA1980;77 (10):6124?8.
  9. Abbas Z, Afzal R. Life cycle and pathogenesis of hepatitis D virus : A review. World J Hepatol 2013;5:666‑
  10. Pascarella S, Negro F. Hepatitis D virus : An update. Liver Int 2011;31:721.
  11. Fattovich G, Gut 2000?,journees fran?aises de luttes contre les hepatites virales .
  12. EuropeanAssociationForTheStudyOfThe Liver .EASL clinical practice guidelines: Man- agementofchronichepatitisBvirusinfection. J Hepatol2012;57(1):167?85.
  13. Hughes SA,WedemeyerH,HarrisonPM. Hepatitisdeltavirus .Lancet 2011;378 (9785):73?85
  14. OliveroA,SmedileA.Hepatitisdeltavirusdiagnosis. Semin Liver Dis 2012;32(3):220?7.
  15. Moradpour D, Negro F. Hepatite D : oubliee mais pas disparue. Rev Med Suisse 2010;6:1656‑
  16. Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG, et al. Anti-HDV IgM as a marker of diseaseactivity in hepatitis delta. PloS One 2014;9(7):e101002.
  17. SorianoV,VispoE,Sierra-EnguitaR,Mendoza de C,Fern?ndez-MonteroJV,etal.Efficacyofprolongedtenofovirtherapyonhepatitis delta inHIV-infectedpatients.AIDSLondEngl 2014;28(16):2389?94.
  18. Calle SerranoB,Gro?hennigA,HomsM, Heidrich B,ErhardtA,DeterdingK,etal. Developmentandevaluationofabaseline- event-anticipationscoreforhepatitisdelta.J Viral Hepat2014;21(11):e154?63.
  19. Abbas Z, Abbas M. Management of hepatitis delta: Need for noveltherapeutic options. World J Gastroenterol 2015; 21:9461‑
  20. European Association for Study of LiverAsociacionLatinoamericana para el EASL-ALEH Clinical Practice Guidelines: Non-invasivetests for evaluation of liver diseaseseverity and prognosis.Journal of Hepatology????????? 2017 vol. 67 j 370?398
  21. STEFANO et al ,GUGLIELMI al,? Jean-Louis FROSSARD et al? et FRANCESCO? NEGRO et al?? ,Rev Med Suisse 2016 ; 12 : 1415-8
  22. Bogomolov P, Alexandrov A, Voronkova?,N, et al. Treatment of chronic hepatitis D withthe entry inhibitormyrcludexB ,firstresults of a Phase Ib / IIastudy. J HepatolPublished Online First : 27 April 2016.
  23. Bazinet M, Pantea V, Cebotarescu V, et al. Significantreduction of HBsAg and HDV RNA by the nucleicacidpolymer REP 2139 in caucasian patients with chronic HBV / HDV co-infection. J Hepatol 2015; 62:S257‑8.
  24. https://www.uptodate.com/contents/treatment-and-prevention-of-hepatitis-d-virus-infection/print,Treatment and prevention of hepatitis D virus infection.2020.

How to Cite This Article

Maryame Elkhayari, Nada. Lahmidani, Hakima Abid, Mariya Lahlali, Asmae Lamine, Mounia Elyousfi, Dafr-Allah Benajah, Mohammed El Abkari and Adil Ibrahimi (2020); QUOI DE NEUF A PROPOS DE LHEPATITE VIRAL D:MISE AU POINT, Int. J. of Adv. Res., 8 (05), 505-511, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/10955

Corresponding Author

EL KHAYARI MARYAME
Service d’hépato-gastro-entérologie, CHU Hassan II de Fès. Faculté de médecine et de pharmacie, Université sidi Mohamed ben Abdallah de Fès.
Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.